Rates of diagnosis and treatment are low, so there is a need for diagnostic tests and biomarkers for classification and ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in biotechnology and healthcare.

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...